Hospital
Jordan Valley Medical Center LP
Jordan Valley Medical Center LP was paid $7.27M by Medicaid between Jan 2018 and Apr 2023, across 159 billing codes. Its largest line is 8888888, Internal/system code - not a standard HCPCS code — 58% of everything it billed.
33Billing provider infoJORDAN VALLEY MEDICAL CENTER LP
WEST JORDAN, UT 84088
WEST JORDAN, UT 84088
33aNPI1033159603assigned 06/08/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$7.27M
24GClaims243,811
24DCodes billed159
24AFirst – last monthJan 2018 – Apr 2023
Compared with peers
Next to other General Acute Care Hospital providers in Utah
Rank by total paid#13 of 26
Median peer was paid$6.14M
This provider vs. median1.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 41,600 | $785K | |
| 2019 | 51,472 | $836K | |
| 2020 | 44,683 | $1.21M | |
| 2021 | 53,195 | $2.01M | |
| 2022 | 48,976 | $2.29M | |
| 2023 | 3,885 | $141K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 8888888 | Internal/system code - not a standard HCPCS code | 58% | 14,523 | 4,690 | $4.23M |
| 36415 | Collection of venous blood by venipuncture | 23% | 19,719 | 16,210 | $1.69M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 3.0% | 1,559 | 1,464 | $216K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 2.9% | 7,112 | 6,528 | $212K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.8% | 1,516 | 692 | $130K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | <1% | 9,496 | 8,495 | $72K |
| 82962 | <1% | 1,168 | 834 | $52K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,012 | 1,848 | $51K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 2,066 | 1,898 | $47K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,391 | 1,303 | $43K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 5,477 | 4,851 | $37K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 8,666 | 7,468 | $37K |
147 more codes
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 884 | $36K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 2,474 | $34K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,584 | $29K |
| 81003 | <1% | 3,619 | $26K | |
| 71045 | Radiologic examination, chest; single view | <1% | 3,173 | $22K |
| 81001 | <1% | 6,387 | $21K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 835 | $20K |
| 87070 | <1% | 442 | $20K | |
| 99285 | Emergency room visit (most serious) | <1% | 8,318 | $20K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,967 | $16K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 322 | $15K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,811 | $12K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 378 | $11K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 207 | $11K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,190 | $11K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 451 | $10K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,632 | $10K |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 450 | $10K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,060 | $10K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 378 | $9K |
| 59025 | Fetal non-stress test | <1% | 997 | $9K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 874 | $8K |
| 84703 | <1% | 3,710 | $8K | |
| 80053 | Comprehensive metabolic panel | <1% | 13,645 | $6K |
| 87088 | <1% | 1,364 | $6K | |
| 87077 | <1% | 1,114 | $5K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 757 | $5K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 82 | $5K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 45 | $4K |
| 81025 | <1% | 562 | $3K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 239 | $3K |
| 87631 | <1% | 82 | $3K | |
| 73130 | <1% | 38 | $3K | |
| 87400 | <1% | 89 | $3K | |
| 82947 | <1% | 48 | $3K | |
| C1758 | Catheter, ureteral | <1% | 127 | $2K |
| 99001 | <1% | 66 | $2K | |
| 73610 | <1% | 36 | $2K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 261 | $2K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 4,401 | $2K |
| 76801 | <1% | 682 | $2K | |
| 80050 | General health panel | <1% | 1,603 | $1K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 763 | $1K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 409 | $1K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 148 | $1K |
| 73630 | <1% | 56 | $1K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 51 | $1K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 28 | $1K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 24 | $976.03 |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 73 | $923.03 |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 14,607 | $896.91 |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 162 | $798.70 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,016 | $794.81 |
| 86710 | <1% | 30 | $759.13 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 6,701 | $739.09 |
| 87081 | <1% | 30 | $645.36 | |
| J3490 | Unclassified drugs | <1% | 216 | $588.51 |
| 93976 | <1% | 82 | $443.86 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 55 | $437.76 |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,543 | $392.82 |
| 93971 | <1% | 55 | $340.07 | |
| 84484 | <1% | 3,327 | $300.54 | |
| A9270 | Non-covered item or service | <1% | 2,850 | $279.32 |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 120 | $234.40 |
| 94760 | <1% | 1,073 | $232.38 | |
| A6402 | Gauze, non-impregnated, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | <1% | 17 | $227.70 |
| 73562 | <1% | 12 | $218.88 | |
| 73030 | <1% | 13 | $218.88 | |
| 85610 | <1% | 1,666 | $173.25 | |
| 83880 | <1% | 966 | $154.96 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,207 | $151.69 |
| G0378 | Hospital observation service, per hour | <1% | 730 | $149.31 |
| 86850 | <1% | 119 | $104.52 | |
| 83690 | <1% | 4,698 | $100.68 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,264 | $84.27 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,572 | $79.06 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 461 | $74.45 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,883 | $68.98 |
| 88142 | <1% | 12 | $67.53 | |
| 84702 | <1% | 1,163 | $58.44 | |
| 87186 | <1% | 1,267 | $54.64 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,314 | $53.53 |
| 85379 | <1% | 1,000 | $51.32 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,099 | $44.20 |
| J2704 | Injection, propofol, 10 mg | <1% | 2,654 | $43.76 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,407 | $39.66 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 710 | $39.63 |
| 86140 | <1% | 629 | $33.31 | |
| 83605 | <1% | 1,798 | $32.58 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 73 | $32.53 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,742 | $31.44 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,818 | $25.30 |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 50 | $24.59 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 202 | $22.50 |
| 86900 | <1% | 939 | $21.18 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,439 | $20.36 |
| 86901 | <1% | 938 | $18.94 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,627 | $15.43 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,188 | $15.24 |
| 80061 | Lipid panel | <1% | 587 | $14.88 |
| 86701 | <1% | 274 | $11.64 | |
| 87040 | <1% | 556 | $11.47 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 26 | $11.37 |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 113 | $10.82 |
| 87205 | <1% | 537 | $10.33 | |
| 85027 | <1% | 545 | $7.98 | |
| 85730 | <1% | 516 | $7.83 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,091 | $7.66 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 882 | $6.84 |
| 85652 | <1% | 644 | $3.10 | |
| 80179 | 0% | 520 | $0.00 | |
| 84439 | 0% | 283 | $0.00 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 90 | $0.00 |
| 80143 | 0% | 539 | $0.00 | |
| 86787 | 0% | 139 | $0.00 | |
| 31720 | 0% | 18 | $0.00 | |
| 99152 | 0% | 123 | $0.00 | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 0% | 121 | $0.00 |
| 87075 | 0% | 12 | $0.00 | |
| 99215 | Doctor's office visit, returning patient (complex) | 0% | 17 | $0.00 |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | 0% | 29 | $0.00 |
| A4649 | Surgical supply; miscellaneous | 0% | 84 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 19 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 14 | $0.00 |
| 87210 | 0% | 26 | $0.00 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 44 | $0.00 |
| 90715 | 0% | 12 | $0.00 | |
| 85007 | 0% | 15 | $0.00 | |
| 83735 | 0% | 322 | $0.00 | |
| 96376 | 0% | 1,765 | $0.00 | |
| 82077 | 0% | 670 | $0.00 | |
| 86308 | 0% | 48 | $0.00 | |
| 82550 | 0% | 78 | $0.00 | |
| 80329 | 0% | 698 | $0.00 | |
| 80320 | 0% | 988 | $0.00 | |
| 82607 | 0% | 13 | $0.00 | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 0% | 40 | $0.00 |
| 88342 | 0% | 213 | $0.00 | |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 139 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 1,324 | $0.00 |
| 94761 | 0% | 82 | $0.00 | |
| 80055 | 0% | 87 | $0.00 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 83 | $0.00 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 0% | 38 | $0.00 |
| 99153 | Mod sedat endo service >5yrs | 0% | 110 | $0.00 |
| 87503 | 0% | 38 | $0.00 | |
| 82150 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialANDERSON, STEVEN (CEO)
| Provider | Location | Paid |
|---|---|---|
| Jordan Valley Medical Center LP | West Valley City, UT | $15.57M |
| Jordan Valley Medical Center LP | West Jordan, UT | $9.07M |
| Jordan Valley Medical Center LP | Lehi, UT | $5.61M |
| Americare Assisted Living, INC | Deltona, FL | $1.41M |
| Jordan Valley Medical Center LP | West Valley City, UT | $65K |
| Crowders Neighborhood Drug Store INC | Bedford, IN | $27K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.